



Assembly Biosciences to Present at Upcoming Investor Conferences

August 28, 2018

SAN FRANCISCO, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), today announced that the company will be participating in the following upcoming investor conferences in September:

- Baird Global Healthcare Conference: Uri Lopatin, MD, Chief Medical Officer, will participate in a fireside chat on September 5, 2018, at 8:30 a.m. E.T. in New York.
- Morgan Stanley Global Healthcare Conference: Richard Colunno, PhD, Executive Vice President and Chief Scientific Officer Virology Operations, will participate in a fireside chat on September 12, 2018, at 10:30 a.m. E.T. in New York.

A live audio webcast of the fireside chat at the Morgan Stanley conference will be available at investor.assemblybio.com, and a replay will be available for approximately 30 days.

About Assembly Biosciences

Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live synthetic biotherapeutic candidates with Assembly's fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL[®] technology. For more information, visit assemblybio.com.

Contacts

Assembly Biosciences, Inc.

Investors:

Lauren Glaser

(415) 521-3828

lglaser@assemblybio.com

 [Primary Logo](#)

Source: Assembly Biosciences